CONSTELLA linaclotide 290 microgram hard capsule bottle

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

linaclotide, Quantity: 0.29 mg

Disponible depuis:

Abbvie Pty Ltd

forme pharmaceutique:

Capsule, hard

Composition:

Excipient Ingredients: calcium chloride dihydrate; hypromellose; microcrystalline cellulose; leucine; titanium dioxide; potable water; Gelatin; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; Shellac; sulfuric acid

Mode d'administration:

Oral

Unités en paquet:

4, 30

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

CONSTELLA is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (IBS-C) and ? chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.

Descriptif du produit:

Visual Identification: White to off-white opaque body and cap, size '2' hard capsules with "FL 290" printed in grey ink on the cap; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Statut de autorisation:

Registered

Date de l'autorisation:

2019-06-18